Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB263T in Advanced NSCLC and Other Solid Tumors
NCT05332574Phase 2Unknown
- Sponsor
- Genor Biopharma
- Start
- May 2022
- Primary completion
- Jun 2024
- Modality
- Antibody Conjugates, Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GB263T in non-small cell lung cancer (NSCLC) and solid tumor, sponsored by Genor Biopharma. Primary endpoints: Adverse Events, Dose Limiting Toxicity and 1 more. Status: unknown.
02
Drugs
GB263T
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT05332574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05332574.